Bli medlem
Bli medlem

Du är här


OASMIA PHARMACEUTICAL AB: Clarification regarding Press Release about Ovarian Cancer Market

Oasmia Pharmaceutical AB
Company Announcement

Clarification regarding Press Release about Ovarian Cancer Market

Uppsala, Sweden, 2016-03-10 22:05 CET (GLOBE NEWSWIRE) --

Oasmia clarifies that the amount of $ 9 million mentioned in today's press
release refers to orders with corresponding sales value to end customers.

About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops new generations of drugs in the field of
human and veterinary oncology. The company’s product development aims to create
and manufacture novel nanoparticle formulations and drug-delivery systems based
on well-established cytostatics which, in comparison with current alternatives,
show improved properties, reduced side-effects, and expanded applications. The
company’s product development is based on its proprietary in-house research and
company patents. Oasmia is listed on NASDAQ Stockholm (OASM.ST), Frankfurt
Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Capital Markets

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.